- Home
- LGCL vs AIFF Comparison
LGCL vs AIFF Comparison
Compare LGCL & AIFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- AIFF
- Stock Information
- Founded
- LGCL 2009
- AIFF 2006
- Country
- LGCL China
- AIFF United States
- Employees
- LGCL N/A
- AIFF N/A
- Industry
- LGCL
- AIFF
- Sector
- LGCL
- AIFF
- Exchange
- LGCL NYSE
- AIFF NYSE
- Market Cap
- LGCL 47.7M
- AIFF 41.5M
- IPO Year
- LGCL 2024
- AIFF N/A
- Fundamental
- Price
- LGCL $1.07
- AIFF $2.74
- Analyst Decision
- LGCL
- AIFF
- Analyst Count
- LGCL 0
- AIFF 0
- Target Price
- LGCL N/A
- AIFF N/A
- AVG Volume (30 Days)
- LGCL 277.5K
- AIFF 1.4M
- Earning Date
- LGCL 01-01-0001
- AIFF 08-18-2025
- Dividend Yield
- LGCL N/A
- AIFF N/A
- EPS Growth
- LGCL N/A
- AIFF N/A
- EPS
- LGCL 0.07
- AIFF N/A
- Revenue
- LGCL $145,690,427.00
- AIFF $139,000.00
- Revenue This Year
- LGCL N/A
- AIFF N/A
- Revenue Next Year
- LGCL N/A
- AIFF N/A
- P/E Ratio
- LGCL $9.92
- AIFF N/A
- Revenue Growth
- LGCL N/A
- AIFF N/A
- 52 Week Low
- LGCL $0.28
- AIFF $1.86
- 52 Week High
- LGCL $3.31
- AIFF $17.20
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- AIFF 36.25
- Support Level
- LGCL N/A
- AIFF $3.03
- Resistance Level
- LGCL N/A
- AIFF $3.21
- Average True Range (ATR)
- LGCL 0.00
- AIFF 0.25
- MACD
- LGCL 0.00
- AIFF -0.04
- Stochastic Oscillator
- LGCL 0.00
- AIFF 3.74
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.